Identification of New Biomarkers of Low-Dose GH Replacement Therapy in GH-Deficient Patients | Zendy

Diana CruzTopete | Zendy; Jens Otto Lunde Jørgensen | Zendy; Britt Christensen | Zendy; Lucila SackmannSala | Zendy; Thomas Krusenstjerna-Hafstrøm | Zendy; Adam Jara | Zendy; Shigeru Okada | Zendy; John J. Kopchick | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Identification of New Biomarkers of Low-Dose GH Replacement Therapy in GH-Deficient Patients

Author(s) -

Diana CruzTopete,

Jens Otto Lunde Jørgensen,

Britt Christensen,

Lucila SackmannSala,

Thomas Krusenstjerna-Hafstrøm,

Adam Jara,

Shigeru Okada,

John J. Kopchick

Publication year - 2011

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2011-0197

Subject(s) - medicine , haptoglobin , endocrinology , apolipoprotein b , gene isoform , biology , biochemistry , cholesterol , gene

GH secretion peaks at puberty and continues to be secreted in adulthood, albeit at a declining rate. Profound GH deficiency (GHD) in adults with pituitary disease is associated with symptoms that improve with GH substitution, but it is important to tailor the GH dose to avoid overtreatment. Measurement of serum IGF-I levels is an important clinical tool in this regard, but it is well recognized that some patients receiving GH treatment do not show an increase in IGF-I.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research